In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
A sub-analysis of previous clinical trial (1) conducted with the EHO-85 hydrogel in the treatment of patients with pressure ulcers, venous ulcers or diabetic foot has recently been published in the journal Pharmaceutics (2). On this occasion, the aim was to analyse the ability of the EHO-85 hydrogel to accelerate wound healing compared to a commonly used reference hydrogel.
A novel mode of action to promote antibiotic-sparing approach to Recurrent UTIs: Questions and Answers on Clinical Practice1
Consultations for recurrent urinary tract infections (rUTIs) in everyday clinical practice range from 1% to 6% of all medical visits with high social and personal associated costs, such as prescriptions, hospital expenses, days of sick leave due to the disease, and the treatment of related comorbidities. Often urologists are asked to give practical recommendations to patients regarding the everyday management of recurrent UTIs. A new review1 aims to give to the physicians managing UTI some helpful suggestions for their everyday clinical practice, based on the recent evidence.
The newer antidiarrheal agents include the mucoprotectants gelatin tannate and xyloglucan. Both were able to attenuate cholera toxin-induced intra-loop water secretion in an experimental study in rats.